What it's for (Indications)
- Bupivacaine, a potent amide-type local anesthetic, is primarily indicated for the production of local or regional anesthesia for surgical procedures, diagnostic and therapeutic blocks, and obstetrical procedures.
- Its prolonged duration of action makes it suitable for extended pain control.
- Specific indications include peripheral nerve blocks (e.
- g.
- , brachial plexus, intercostal, lumbar plexus), sympathetic nerve blocks, caudal blocks, epidural blocks for labor and delivery or post-operative pain management, subarachnoid (spinal) blocks, retrobulbar blocks, and infiltration anesthesia.
- The choice of concentration and volume depends heavily on the specific procedure, desired depth and duration of anesthesia, and individual patient factors.
- It is frequently employed when a longer duration of sensory block is clinically advantageous and motor blockade, if present, is acceptable, providing effective and sustained analgesia for various medical interventions.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage of bupivacaine is highly individualized and must be determined by the clinician based on the specific anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, the depth of anesthesia required, the duration of the block, the individual patient's physical status, and the presence or absence of epinephrine. Typical concentrations range from 0.25% to 0.75%, with or without epinephrine (1:200,000 solution) to prolong the duration of action and reduce systemic absorption. For epidural anesthesia, doses may range from 5 to 30 mL of a 0.25% to 0.75% solution. For peripheral nerve blocks, volumes up to 30-50 mL of 0.25% or 0.5% solution might be used, staying within maximum recommended limits. The maximum recommended single dose generally should not exceed 175 mg (approximately 35 mL of 0.5% solution) without epinephrine, or 225 mg (approximately 45 mL of 0.5% solution) with epinephrine, over a 4-hour period. Doses must be carefully titrated, and the smallest effective dose should always be used to minimize the risk of systemic toxicity. Continuous infusions often utilize lower concentrations, such as 0.0625% to 0.125% for prolonged analgesia. |
Safety & Warnings
Common Side Effects
- Systemic toxicity from bupivacaine can manifest as central nervous system (CNS) and cardiovascular effects, which are the most serious adverse reactions.
- CNS effects typically precede cardiovascular effects and include lightheadedness, dizziness, tinnitus, blurred vision, perioral numbness, tremors, twitching, disorientation, somnolence, and can progress to convulsions, respiratory depression, and even respiratory arrest.
- Cardiovascular effects include hypotension, bradycardia, cardiac arrhythmias, and can culminate in cardiac arrest, which is often difficult to treat with bupivacaine.
- Local adverse effects can include pain at the injection site, swelling, and bruising.
- Neurological complications from regional blocks may involve persistent paresthesia, sensory or motor deficits, nerve injury, or cauda equina syndrome.
- Allergic reactions, though rare, can range from urticaria and rash to severe anaphylaxis.
- Other potential side effects include nausea, vomiting, urinary retention, headache, and rarely, methemoglobinemia.
Serious Warnings
- Black Box Warning: The 0.75% concentration of bupivacaine is NOT recommended for obstetric epidural anesthesia due to the significantly increased risk of refractory cardiac arrest and death compared to other bupivacaine concentrations when used for this specific indication. Local anesthetic systemic toxicity (LAST), particularly with bupivacaine, can lead to severe cardiovascular collapse and central nervous system manifestations such as seizures. Resuscitation from bupivacaine-induced cardiotoxicity can be exceptionally challenging and requires immediate access to advanced cardiac life support protocols, including prompt administration of intravenous lipid emulsion therapy. All regional anesthetic procedures must be performed by clinicians thoroughly trained in the diagnosis and management of systemic toxicity and other acute adverse reactions. Essential resuscitative equipment and drugs, including lipid emulsion, must be immediately available for the management of potential toxicity during or immediately after bupivacaine administration, emphasizing the critical need for vigilance and preparedness.
- Bupivacaine carries a significant risk of systemic toxicity, particularly severe cardiovascular effects, when administered in excessive doses, or through inadvertent intravascular injection.
- Resuscitation equipment and personnel trained in managing local anesthetic toxicity must be immediately available whenever bupivacaine is administered.
- Particular caution is advised in patients with pre-existing cardiac disease, severe hepatic impairment, or in elderly and debilitated patients who may be more susceptible to systemic toxicity.
- Blocks in highly vascular areas, such as the head and neck, carry an increased risk of rapid systemic absorption and toxicity.
- The 0.
- 75% solution is particularly associated with difficult-to-treat cardiac arrest and is contraindicated for obstetric epidural anesthesia.
- Close monitoring of vital signs and patient symptoms is crucial during and after administration.
- Continuous intra-articular infusion of local anesthetics, including bupivacaine, following arthroscopic procedures has been associated with post-arthroscopic glenohumeral chondrolysis, a condition characterized by progressive cartilage destruction.
- Methemoglobinemia is a rare but serious potential adverse effect of local anesthetics that requires careful monitoring, especially in pediatric patients or those with underlying conditions.
How it Works (Mechanism of Action)
Bupivacaine functions as an amide-type local anesthetic by reversibly binding to voltage-gated sodium channels located in the nerve membranes. This interaction impedes the rapid influx of sodium ions across the nerve cell membrane, which is a critical event for the initiation and propagation of nerve impulses. By stabilizing the neuronal membrane and increasing the threshold for electrical excitation, bupivacaine effectively prevents the generation and conduction of action potentials along the nerve fibers. This blockade results in a temporary loss of sensation (anesthesia) and/or motor function in the region innervated by the affected nerves. Its relatively high lipid solubility and protein binding contribute to its longer duration of action compared to other local anesthetics like lidocaine, as these properties facilitate its accumulation within nerve sheaths and slow its diffusion away from the target site, enhancing the sustained blockade of pain signals. This differential blockade typically affects small, unmyelinated pain fibers more readily than larger motor fibers, allowing for sensory anesthesia with relatively less motor blockade at lower concentrations.